FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No: L24239MH1987PLC043662

Date: 21st April, 2023

To, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001

BSE Scrip Code: 539730

Sub: Statement of deviation or variation in the use of proceeds of Preferential Issue.

Dear Sir/ Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that there is no deviation or variation in the use of proceeds, from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated August 27, 2022.

A statement confirming that there is no deviation or variation in the utilisation of these proceeds for quarter ended March 31, 2023, duly reviewed by the Audit Committee is attached.

You are requested to take the same on record.

Thanking you.

For Fredun Pharmaceuticals Limited

Jinkal Shah (Jinkal Soni) Company Secretary and Compliance Officer

Encl: as above

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No: L24239MH1987PLC043662



Statement of Deviation/ Variation in utilization of funds raised:

Name of the Listed Entity	Fredun Pharmaceuticals Limited		
Mode of Fund	Preferential Allotment		
Date of Raising Funds	December 27, 2022		
Amount Raised	1.74 cr.		
Report filed for Quarter ended	March 31, 2023		
Monitoring Agency	Not Applicable		
Monitoring Agency Name, if applicable	Not Applicable		
Is there a Deviation / Variation in use of	No		
funds raised			
If yes, whether the same is pursuant to	Not Applicable		
change in terms of a contract or objects,			
which was approved by the shareholders			
If Yes, date of Shareholder Approval	Not Applicable		
Explanation for Deviation / Variation	Not Applicable		
7			
Comments of the Audit Committee after	No		
review			
Comments of the auditors, if any	Not Applicable		

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No: L24239MH1987PLC043662

following table Original Object	Modified Object, if any	Original Allocation (Rs.in Lakhs)	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks, if any
The object of the Company for proposed preferential issue is to penetrate further in the domestic, developing and new international markets with its new line of products by way of augmenting its manufacturing capacities in the pet care and nutrition sector.	Not Applicable	1.74 cr.		1.74 cr.	There has been no deviation/ variation in utilization of funds raised through Preferential Issue for the quarter	N.A.

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

For Fredun Pharmaceuticals Limited

Jinkal Shah (Jinkal Soni) Company Secretary and Compliance Officer